The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and tolerability of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer.
 
Tomas Lyons
No Relationships to Disclose
 
Ayca Gucalp
Research Funding - Innocrin Pharma; Pfizer
 
Artavazd Arumov
No Relationships to Disclose
 
Sujata Patil
No Relationships to Disclose
 
Marcia Edelweiss
No Relationships to Disclose
 
Mila Gorsky
No Relationships to Disclose
 
Tiffany A. Troso-Sandoval
No Relationships to Disclose
 
Jacqueline Bromberg
No Relationships to Disclose
 
Rachel Ann Sanford
No Relationships to Disclose
 
Neil M. Iyengar
No Relationships to Disclose
 
Shanu Modi
Speakers' Bureau - Genentech
Research Funding - Daiichi Sankyo; Novartis; Roche/Genentech; Seagen; Synta
 
Ranju Gupta
No Relationships to Disclose
 
Tiffany A. Traina
Consulting or Advisory Role - Advaxis; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Celgene; Eisai; Genentech/Roche; Genomic Health; Innocrin Pharma; Medivation; Merck; Pfizer; Puma Biotechnology; Samsung
Speakers' Bureau - Roche/Genentech
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Eisai (Inst); Innocrin Pharma (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst)